González-Ortiz, A.; Pulido-Capiz, A.; Castañeda-Sánchez, C.Y.; Ibarra-López, E.; Galindo-Hernández, O.; Calderón-Fernández, M.A.; López-Cossio, L.Y.; DÃaz-Molina, R.; Chimal-Vega, B.; SerafÃn-Higuera, N.;
et al. eIF4A/PDCD4 Pathway, a Factor for Doxorubicin Chemoresistance in a Triple-Negative Breast Cancer Cell Model. Cells 2022, 11, 4069.
https://doi.org/10.3390/cells11244069
AMA Style
González-Ortiz A, Pulido-Capiz A, Castañeda-Sánchez CY, Ibarra-López E, Galindo-Hernández O, Calderón-Fernández MA, López-Cossio LY, DÃaz-Molina R, Chimal-Vega B, SerafÃn-Higuera N,
et al. eIF4A/PDCD4 Pathway, a Factor for Doxorubicin Chemoresistance in a Triple-Negative Breast Cancer Cell Model. Cells. 2022; 11(24):4069.
https://doi.org/10.3390/cells11244069
Chicago/Turabian Style
González-Ortiz, Alina, Angel Pulido-Capiz, César Y. Castañeda-Sánchez, Esmeralda Ibarra-López, Octavio Galindo-Hernández, Maritza Anahà Calderón-Fernández, Leslie Y. López-Cossio, Raul DÃaz-Molina, Brenda Chimal-Vega, Nicolás SerafÃn-Higuera,
and et al. 2022. "eIF4A/PDCD4 Pathway, a Factor for Doxorubicin Chemoresistance in a Triple-Negative Breast Cancer Cell Model" Cells 11, no. 24: 4069.
https://doi.org/10.3390/cells11244069
APA Style
González-Ortiz, A., Pulido-Capiz, A., Castañeda-Sánchez, C. Y., Ibarra-López, E., Galindo-Hernández, O., Calderón-Fernández, M. A., López-Cossio, L. Y., DÃaz-Molina, R., Chimal-Vega, B., SerafÃn-Higuera, N., Córdova-Guerrero, I., & GarcÃa-González, V.
(2022). eIF4A/PDCD4 Pathway, a Factor for Doxorubicin Chemoresistance in a Triple-Negative Breast Cancer Cell Model. Cells, 11(24), 4069.
https://doi.org/10.3390/cells11244069